Gadoxetate disodium Pregnancy and Breastfeeding Warnings
Medically reviewed by Drugs.com. Last updated on Jul 14, 2022.
Gadoxetate disodium is also known as: Eovist
Gadoxetate disodium Pregnancy Warnings
Gadoxetate has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity. There are no controlled data in human pregnancy. Gadoxetate is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.
Gadoxetate disodium Breastfeeding Warnings
Based on pharmacokinetics of gadoxetate, women with normal renal function may resume nursing with milk produced 10 hours or more following gadoxetate administration with minimal risk for the presence of the drug within the milk
There are no data on the excretion of gadoxetate into human milk. The effects in the nursing infant are unknown. The manufacturer recommends that caution be used when administering gadoxetate to nursing women.
See also
References for pregnancy information
- "Product Information. Eovist (gadoxetate)." Bayer Pharmaceutical Inc (2008):
References for breastfeeding information
- "Product Information. Eovist (gadoxetate)." Bayer Pharmaceutical Inc (2008):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.